Abbott Laboratories Reports 6.9% Revenue Growth in Q3 2025, Driven by Medical Devices and Pharmaceuticals

Abbott Laboratories reported a notable increase in its financial performance for the third quarter and the first nine months of 2025, with net sales reaching $11.4 billion and $32.9 billion, respectively. This represents a 6.9% increase in quarterly sales compared to $10.6 billion in the same period last year, and a 6.1% increase in year-to-date sales from $31.0 billion. The company's operating earnings also improved, totaling $2.1 billion for the third quarter and $6.1 billion for the nine months, up from $1.9 billion and $5.0 billion in the prior year periods. Net earnings for the third quarter were $1.6 billion, consistent with the previous year, while year-to-date net earnings increased to $4.7 billion from $4.2 billion.

The growth in revenue was primarily driven by strong performance in the Medical Devices and Established Pharmaceutical Products segments, which saw increases of 14.8% and 7.5%, respectively, in the third quarter. However, the Diagnostic Products segment experienced a decline of 6.6% in quarterly sales, largely due to reduced demand for COVID-19 testing, which generated $69 million in the third quarter of 2025 compared to $265 million in the same quarter of 2024. The company noted that international sales were particularly strong, with a 9.9% increase in the third quarter, aided by favorable foreign exchange rates.

Abbott has also been active in strategic developments, including the launch of new products and regulatory approvals. In March 2025, the company received CE Mark approval for its Volt™ Pulsed Field Ablation System, and in May, it announced FDA approval for the Tendyne™ transcatheter mitral valve replacement system. Additionally, Abbott's restructuring plans aimed at streamlining operations in its diagnostic and medical devices businesses resulted in $197 million in severance and other charges during the first nine months of 2025.

Operationally, Abbott's workforce has seen changes, with a total employee headcount reflecting ongoing restructuring efforts. The company reported a total of $6.3 billion in net cash from operating activities for the first nine months of 2025, an increase from $5.7 billion in the prior year, indicating improved operational efficiency. The company’s cash and cash equivalents stood at $7.5 billion as of September 30, 2025, slightly down from $7.6 billion at the end of 2024, primarily due to debt repayments and dividend payments.

Looking ahead, Abbott anticipates continued growth driven by its diverse product portfolio and strategic initiatives. The company expects to maintain its investment-grade credit rating and plans to continue its share repurchase program, having repurchased 2.4 million shares for $303 million in the third quarter. Abbott's management remains optimistic about future performance, despite challenges in the diagnostic segment and ongoing market conditions.